Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).

Published

Journal Article

Cardiorenal syndromes (CRS) have been recently classified into five distinct entities, each with different major pathophysiologic mechanisms. CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output after the first several doses of intravenous diuretics. Altered cardiac and renal hemodynamics are believed to be the most important determinants of CRS type 1. CRS type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure. Accelerated renal cell apoptosis and replacement fibrosis is considered to be the dominant mechanism. CRS type 3 is acutely decompensated heart failure after acute kidney injury from inflammatory, toxic, or ischemic insults. This syndrome is precipitated by salt and water overload, acute uremic myocyte dysfunction, and neurohormonal dysregulation. CRS type 4 is manifested by the acceleration of the progression of chronic heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy', is believed to be the predominant pathophysiologic mechanism. Type 5 CRS is simultaneous acute cardiac and renal injury in the setting of an overwhelming systemic insult such as sepsis. In this scenario, the predominant pathophysiological disturbance is microcirculatory dysfunction as a result of acutely abnormal immune cell signaling, catecholamine cellular toxicity, and enzymatic activation which result in simultaneous organ injury often extending beyond both the heart and the kidneys. This paper will summarize these and other key findings from an international consensus conference on the spectrum of pathophysiologic mechanisms at work in the CRS.

Full Text

Cited Authors

  • McCullough, PA; Kellum, JA; Haase, M; Müller, C; Damman, K; Murray, PT; Cruz, D; House, AA; Schmidt-Ott, KM; Vescovo, G; Bagshaw, SM; Hoste, EA; Briguori, C; Braam, B; Chawla, LS; Costanzo, MR; Tumlin, JA; Herzog, CA; Mehta, RL; Rabb, H; Shaw, AD; Singbartl, K; Ronco, C

Published Date

  • 2013

Published In

Volume / Issue

  • 182 /

Start / End Page

  • 82 - 98

PubMed ID

  • 23689657

Pubmed Central ID

  • 23689657

Electronic International Standard Serial Number (EISSN)

  • 1662-2782

Digital Object Identifier (DOI)

  • 10.1159/000349966

Language

  • eng

Conference Location

  • Switzerland